Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Jean François Seitz, Florence Castan et al.|JAMA Oncology|2022Cited by 322
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 studyDo‐Youn Oh, Juan W. Valle, Masayuki Kitano et al.|The Lancet. Gastroenterology & hepatology|2024Cited by 245
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trialThierry Conroy, Christophe Borg, Florence Castan et al.|Annals of Oncology|2024Cited by 187